Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

5 Mar 2015

Abstract excerpt

// David Chiron 1 , Christelle Dousset 1, 2, 3, * , Carole Brosseau 1, * , Cyrille Touzeau 1, 2 , Sophie Maïga 1, 2 , Philippe Moreau 1, 2 , Catherine Pellat-Deceunynck 1, 2 , Steven Le Gouill 1, 2, 3 , Martine Amiot 1, 2 1 INSERM, UMR892 - CNRS, UMR 6299, Université de Nantes, France 2 Service d’Hématologie Clinique, Unité d’Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France 3 CIC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25797245
DOI: 10.18632/oncotarget.3275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphomaPMID 25797245Read ↗

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphomaSemantic proximity Read ↗

Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

The B cell receptor signaling pathway in mantle cell lymphomaSemantic proximity Read ↗

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphomaSemantic proximity Read ↗

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionSemantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.Semantic proximity Read ↗

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.